No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - US healthcare company Johnson & Johnson raised on Wednesday lifted annual earnings and sales guidance on the back of strong sales and foreign exchange tailwinds, sending shares in the firm up 5.5%.
The drug and medical equipment maker posted a rise in second-quarter sales to $23.7bn year-on-year, beating the $22.8bn forecast by analysts. Earnings per share came in at $2.77 compared with estimates of $2.68.
Adjusted sales growth for the full year was now expected to be 3.2 - 3.7%, up from 2-3%. J&J now expects full-year sales, including the impact of foreign currency, in the range of $93.2bn - $93.6bn, up from an April forecast of $91bn - $91.8bn when the company said it was $400m in costs related to tariffs.
Reporting by Frank Prenesti for Sharecast.com
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.